Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930328 · ClinicalTrials.gov registry record
Retrospective Real World Oxbryta® Data Collection and Analysis Study
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 216
- Enrollment target
NCT04930328: Completed study, sponsored by Pfizer.
NCT04930328 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 216 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04930328 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 216 participants
- Enrollment target
Study Summary
The aim of this study is to collect and analyze retrospective data on Oxbryta in a real-world setting. This is a multicenter, retrospective data collection and analysis study to characterize health outcomes in approximately 300 patients with SCD who have been treated with Oxbryta as part of their usual care. Any patient with SCD who received Oxbryta treatment for at least 2 weeks as part of their usual care according to the Oxbryta US Prescribing Information (USPI) is eligible to participate. Study data from 1 year before and up to 1 year after the first dose of Oxbryta will be entered in case report forms (CRFs) via an electronic data capture (EDC) system by the study staff.
Interventions
- DRUG Oxbryta® (voxelotor) 500-mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2021-03-20 |
| Est. Completion | 2022-02-25 |
What the finished NCT04930328 record still lists
NCT04930328 is an observational study that tracks outcomes without assigning an intervention. The registered 216 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Oxbryta® (voxelotor) 500-mg Tablets is the first listed.
NCT04930328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04930328 about?
NCT04930328 is a clinical study titled "Retrospective Real World Oxbryta® Data Collection and Analysis Study". The aim of this study is to collect and analyze retrospective data on Oxbryta in a real-world setting. This is a multicenter, retrospective data collection and analysis study to characterize health outcomes in approximately 300 patients with SCD who have been treated with Oxbryta as part of their us...
What is the current status of trial NCT04930328?
This trial is currently completed. The enrollment target is 216 participants. The study started on 2021-03-20. Estimated completion is 2022-02-25.
What interventions are being tested in trial NCT04930328?
The interventions under investigation include: Oxbryta® (voxelotor) 500-mg Tablets (DRUG).
Who is sponsoring clinical trial NCT04930328?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02609685 · 216 participants · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
- NCT04994873 · 216 participants · NA
Skills to Enhance Positivity in Suicidal Youth
- NCT05264779 · 216 participants · NA
The Periviable GOALS Decision Support Tool
- NCT05434130 · 216 participants · Phase 2
Modulating Exercise Dosage to Improve Concussion Recovery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI